Effect of CSL112 (apolipoprotein A‐I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross‐study comparison by Bo Zheng, Shinya Goto, Regina Clementi, John Feaster, Danielle Duffy, Penelope Dalitz, Jolanta Airey, Serge Korjian, Michael A. Tortorici, John Roberts, C. Michael Gibson

Connect to this object online.

First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor by Hidetoshi Shimizu, Michael A. Tortorici, Yoshiyasu Ohta, Kei Ogawa, Sheikh Mohammed Ashfaq Rahman, Aya Fujii, Yuki Hiraga, Mizue Kawai, Kanami Sugimoto‐Kawabata, Mattheus (Thijs), Jan Jaap vanLier, Stephen Djedjos, B. T. Slingsby, David M. Rodman

Connect to this object online.

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy by Michael A. Tortorici, Theresa Yuraszeck, David Cornblath, Vera Bril, Hans‐Peter Hartung, Gen Sobue, Richard A. Lewis, Ingemar S. J. Merkies, John‐Philip Lawo, Michaela Praus, Billie L. Durn, Orell Mielke, Xuewen Ma, Petra Jauslin, Marc Pfister, Ivo N. vanSchaik, the PATH study group

Connect to this object online.